Cancer

FDA Grants Breakthrough Designation to Melanoma Risk Assessment Test

The molecular test combines clinical variables and gene expression profiling to evaluate metastatic risk in patients with early-stage skin cancer.

Cancer

Labcorp Launches RNA-Based At-Home Colorectal Cancer Test Nationwide

The test detect signs of colorectal cancer and precancerous growths using a home collection kit.

Cancer

Myriad Genetics Launches Prostate Cancer Test Combining Genomics and AI

The test combines genomic risk assessment and digital pathology analysis to help clinicians tailor monitoring strategies.

Urine Test Reduced Unnecessary Prostate Biopsies by 64%, Study Finds

Jun 8, 2026 | Prostate

Researchers reported that the test reduced unnecessary biopsies by up to 64% without compromising detection of aggressive prostate cancers.

Labcorp Expands DPYD Test to Identify Chemotherapy Toxicity Risk

Jun 8, 2026 | Cancer, Company News, Molecular Diagnostics

The updated test includes additional DPYD variants recommended by the Association for Molecular Pathology to help identify patients who may be at risk for severe chemotherapy side effects.

Blood Test Boosts Lung Cancer Screening Participation

Jun 8, 2026 | Lung Cancer, Molecular Diagnostics

New clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with low-dose CT screening alone.

Study Shows Blood Test Predicts Breast Cancer Recurrence Years Before Clinical Symptoms

Jun 5, 2026 | Breast, Molecular Diagnostics

Monitoring circulating tumor DNA dynamics outperformed standard markers for predicting survival and relapse in early-stage patients.

Blood Test for Colon Cancer Improves Chemotherapy Decisions, Study Finds

Jun 5, 2026 | Colorectal, Molecular Diagnostics

The study demonstrated that patients who test positive for ctDNA “actually benefit from chemotherapy.”

Study: New Mapping Method Improves Detection of Leukemia Abnormalities

Jun 4, 2026 | Cancer, Leukemia, Molecular Diagnostics

Research shows optical genome mapping identifies genomic changes in nearly 98% of T-cell acute lymphoblastic leukemia cases compared to 55% with traditional analysis.